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Introduction
Type I NKT cells (NKTs) are an evolutionarily conserved subset 
of innate lymphocytes that express invariant T cell receptor (TCR) 
α-chain Vα24-Jα18 and react to self- or microbial-derived glyco-
lipids presented by the monomorphic HLA class I–like molecule 
CD1d (1–4). The potential importance of NKTs for tumor immu-
nity and immunotherapy has been demonstrated in multiple 
models of cancer in mice and in early-stage clinical trials in can-
cer patients (5–10). In contrast to T cells, NKTs effectively traffic 
to the tumor site and can mediate antitumor responses via either 
direct killing of CD1d+ tumor cells, inhibition of tumor-supportive 
macrophages, or transactivation of NK cells (11). Several studies 
have revealed strong positive associations between the numbers 
of tumor-infiltrating or circulating NKTs and improved disease 
outcome in patients with diverse tumor types (6, 12–15). Con-
versely, tumor progression is often accompanied by a decrease 
in NKT number or functional activity (16), or the downregulation 
of CD1d expression on malignant cells (17). To counteract these 
tumor escape mechanisms, we developed methods to expand pri-
mary human NKTs to clinical scale ex vivo and to redirect their 
cytotoxicity against tumor cells via transgenic expression of chi-
meric antigen receptors (CARs) (18). Similar to the observations 
reported in CAR-T cell clinical trials (19, 20), there is a strong cor-
relation between the antitumor efficacy and in vivo persistence of 
CAR-NKT products in a xenogenic tumor model (18). However, 
the mechanisms that govern ex vivo expansion and subsequent in 
vivo persistence of human NKTs remain largely unknown, imped-
ing rational design of NKT-based cancer immunotherapy.
Recent global transcriptional profiling studies demonstrated 
that NKTs, though they share properties with T and NK cells, 
are a distinct population of lymphocytes (21). In the mouse, the 
developmental program and functional differentiation of NKTs 
have been characterized quite extensively during the last decade, 
as summarized in recent reviews (4, 22). Several key features of 
murine NKTs have also been confirmed in their human counter-
parts. Both in mice and in humans, NKTs diverge from T cells at 
the stage of CD4+CD8+ (double-positive, DP) thymocytes. Unlike 
T cells, which are positively selected by thymic epithelial cells, 
NKTs are selected by CD1d-expressing DP thymocytes (23). The 
expression of promyelocytic leukemia zinc finger transcription 
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superior developmental potential and could support ex vivo expan-
sion of NKTs for therapeutic applications. To test this hypothesis, 
we performed immunophenotyping of primary NKTs immediately 
after isolation from peripheral blood and at different time inter-
vals in culture after stimulation with αGalCer, which consistently 
produced higher frequency and absolute numbers of NKTs com-
pared with the use of a T cell expansion protocol based on CD3/
CD28 stimulation (Supplemental Figure 2). Despite a notable 
interindividual variability of CD62L expression in freshly isolated 
NKTs, we observed a striking accumulation of CD62L+ fraction of 
NKTs from 33.63% ± 27.62% in freshly isolated NKTs to 69.92% 
± 10.57% on day 12 of the culture (P < 0.001, Figure 1, A and B). 
Although CD62L was more frequently expressed on CD4+ NKTs 
both before and after culture, the accumulation of CD62L+ cells 
could not be explained by a preferential expansion of CD4+ NKTs. 
Indeed, at the end of a 12-day culture, the frequency of CD62L+, 
CD4+, and CD62L+CD4+ NKTs increased 3.9 ± 1.8–fold, 1.9 ± 0.7–
fold, and 3.8 ± 1.9–fold, respectively. Consistent with these results, 
we also observed an enrichment of the CD62L+CD4– subset at day 
12 compared with day 0 (Supplemental Figure 1B). Further multi-
parameter characterization of NKTs showed that CD62L was often 
coexpressed with CCR7 before culture, but CCR7 expression was 
progressively lost during culture (Supplemental Figure 1C). We also 
found that nearly all NKTs expressed both CD27 and CD28 before 
culture. While CD27 was downregulated in about half of NKTs by 
day 12 of culture irrespective of CD62L status, CD28 expression 
remained intact (Supplemental Figure 1C).
CD62L– cells expressed higher levels of CD161 and CD56 
(NK-like differentiation), but a lower level of IL-7Rα (Supple-
mental Figure 1D). While freshly isolated NKTs rarely expressed 
exhaustion markers (PD-1, LAG-3, or TIM-3) in either the CD62L+ 
or the CD62L– subset, the CD62L– subset preferentially expressed 
PD-1 and TIM-3 at day 12 of NKT culture (P = 0.0043, 0.0184, 
Figure 1C). Moreover, immune-related gene expression analysis 
(nCounter platform) of CD62L+ and CD62L– NKTs sorted on day 
12 revealed mRNA upregulation of genes associated with T cell 
survival/memory (e.g., LEF1, S1PR1, IL7RA, IL21R) in CD62L+ 
NKTs and with exhaustion/terminal differentiation in CD62L– 
NKTs (e.g., PD1, LAG3, TIM3, CD244, CD161, CD56; Figure 1D 
and Supplemental Table 1). The transcription factor lymphoid 
enhancer factor 1 (LEF1) was the top immune-related gene over-
expressed in CD62L+ compared with CD62L– NKTs. Intracellular 
flow cytometry analysis demonstrated that CD62L+ NKTs uni-
formly expressed LEF1, whereas a major fraction of CD62L– cells 
was LEF1-negative. Since LEF1 was recently shown to mediate 
expansion of murine NKT precursors in part via transcriptional 
activation of GATA3 gene expression (39), we analyzed the level 
of GATA3 protein in human NKTs in relation to LEF1 and CD62L 
levels. We found that GATA3 expression strongly correlated with 
the expression of LEF1 and CD62L in human NKTs (Supplemen-
tal Figure 1E). Interestingly, CD62L+ and CD62L– NKTs expressed 
the same level of PLZF, a transcriptional master regulator of NKT 
functional differentiation (21). Thus, the CD62L+ subset predomi-
nantly accumulates in culture upon antigenic stimulation of pri-
mary NKTs, and loss of CD62L expression is associated with NK-
like terminal differentiation, exhaustion, and downregulation of 
pro-proliferative transcriptional regulators.
factor (PLZF) immediately after positive selection enables intra-
thymic expansion and effector-memory–like differentiation of 
NKTs (24). Peripheral NKTs are long-lived lymphocytes, and their 
post-thymic maintenance largely depends on slow IL-15–mediat-
ed homeostatic proliferation (25, 26). In human peripheral blood, 
NKTs are divided into 2 major functional subsets based on CD4 
expression: CD4+ and CD4– (mostly CD8/CD4–double-negative, 
DN) (27). The CD4+ subset is highly enriched in neonate NKTs and 
undergoes fewer homeostatic divisions compared with the CD4– 
subset in adults (26), suggesting that CD4+ NKTs could contribute 
to the long-term persistence of adoptively transferred therapeu-
tic NKTs under certain conditions. However, ex vivo expansion 
of human NKTs in response to antigenic stimulation, e.g., with 
α-galactosylceramide (αGalCer), produces similar numbers of 
CD4+ and DN NKTs (28). NKTs also exhibit an NK-like linear dif-
ferentiation with acquisition of CD161 and then CD56 expression. 
Like in T cells, the expression of CD56 is associated with terminal 
differentiation and the loss of proliferative potential (29).
In contrast to peripheral T cells, which have a well-estab-
lished developmental hierarchy from naive to central-memory to 
effector-memory to terminal effector cells (30), NKTs are broadly 
described as cells with “activated memory” phenotype without the 
naive state (31, 32). In cord blood, the majority of NKTs are CD4+ 
and coexpress CD45RO with CD62L and CCR7 without immedi-
ate effector function (26, 31, 33), thus resembling central-memo-
ry CD4 T cells. In adult peripheral blood, NKTs are equally split 
between CD4+ and CD4– subsets (albeit with significant interindi-
vidual variability). Adult NKTs lack a clear demarcation between 
“memory” and “effector” states, as they variably express memory 
markers and have immediate effector functions such as cytokine 
production and cytotoxicity (26, 33). The majority of adult NKTs 
even in the elderly express CD28 (34), making them distinct from 
terminally differentiated T effector cells (35).
Recent reports have demonstrated that CD62L+ central mem-
ory T cells have stem cell properties and superior therapeutic activ-
ity in cell therapy products (36–38). The functional significance of 
CD62L expression in NKTs remains unknown. In this study, we 
found that the CD62L+ subset is required for NKT ex vivo expan-
sion and in vivo persistence. Importantly, when engineered to 
express CD19-specific CAR (CAR.CD19), CD62L+ but not CD62L– 
CAR.CD19 NKTs produced sustained tumor regression in a B cell 
lymphoma model in NOD/SCID/IL-2Rγ(null) (NSG) mice. We 
also found that CD62L+ NKTs could be maintained during ex vivo 
expansion when provided with certain costimulatory ligands. With 
this knowledge, we engineered costimulatory artificial antigen-pre-
senting cells (aAPCs) that can be used to generate NKTs and CAR-
NKTs with superior therapeutic activity in patients with cancer.
Results
CD62L+ cells accumulate in culture upon antigenic stimulation of pri-
mary NKTs. Previous studies that compared the phenotype of human 
NKTs in adult peripheral blood with that in cord blood observed 
much higher proportions of CD4+ and CD62L+ NKTs in neonates 
(refs. 26, 31, 33; and Supplemental Figure 1A; supplemental materi-
al available online with this article; doi:10.1172/JCI83476DS1). The 
prevalence of CD4+CD62L+ NKTs in cord blood suggests that the 
expression of CD4 or/and CD62L marks a subset of NKTs that has 
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
2 3 4 3jci.org   Volume 126   Number 6   June 2016
Th0-like polarization (a balanced production of IFN-γ and IL-4, 
typical of the whole population of peripheral blood NKTs), whereas 
the polarization profile of CD62L– cells could not be determined 
unambiguously because of the low absolute amounts of each cyto-
kine. Despite strong upregulation of IL23R mRNA expression in 
the CD62L– subset as determined by the nCounter analysis (Figure 
1D; a potential Th17 polarization), we detected neither IL-23R pro-
tein expression on the cell surface of NKTs by FACS nor production 
of IL-17 upon TCR-stimulation by ELISA (data not shown).
CD62L+ NKTs have superior survival and proliferative capacity 
upon secondary stimulation. To examine whether the accumula-
CD62L+ and CD62L– NKTs have comparable cytotoxicity, but 
the CD62L+ subset is the main source of cytokines. We magnetically 
sorted NKTs from primary culture into CD62L+ and CD62L– sub-
sets and examined their functional properties. Figure 2A dem-
onstrates that either both subsets were equally cytotoxic (3 of 6 
donors) or CD62L– NKTs were more cytotoxic than CD62L+ NKTs 
(3 of 6 donors) against CD1d+ DAOY medulloblastoma cells when 
the target cells were pulsed with αGalCer. The analysis of cytokine 
production in αGalCer-stimulated NKTs revealed much higher lev-
els of both IFN-γ and IL-4 production by CD62L+ compared with 
CD62L– subsets (P < 0.001, Figure 2B). CD62L+ cells exhibited a 
Figure 1. Accumulation of CD62L+ subset in culture after in vitro antigenic stimulation of primary NKTs. (A) CD62L expression was examined by FACS 
in primary NKTs from freshly isolated PBMCs (day 0) and 12 days after stimulation with αGalCer and in vitro expansion in culture (n = 10). (B) Kinetics of 
CD62L expression in NKTs at the indicated intervals after primary stimulation (as in A) from individual donors (n = 10). (C) Expression of PD-1, TIM-3, and 
LAG-3 on NKT surface was measured by FACS on days 0 and 12 (top panel). Representative plots from 1 of 4 donors (middle panel) or mean ± SD of mean 
fluorescence intensity (MFI) for all donors (n = 4, bottom panel). (D) On day 12 after primary stimulation, NKTs were magnetically sorted into CD62L+ 
and CD62L– subsets followed by RNA isolation and gene expression analysis using Human Immunology Panel version 2 and nCounter Analysis System 
(NanoString). The heat map shows the log2 fold changes (CD62
+/CD62L–) of genes with P values less than 0.02 and average fold change greater than 2. 
Data were generated from 6 NKT donors (12 paired samples). **P < 0.01, ***P < 0.001, paired t test.
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bottom panel). Therefore, CD62L+ NKTs survive and proliferate 
in response to antigenic stimulation and are responsible for NKT 
numeric expansion in culture.
CD62L+ subset is responsible for in vivo persistence and thera-
peutic activity of NKTs. To determine the role of the CD62L+ sub-
set in the in vivo persistence of adoptively transferred NKTs, we 
transduced NKTs with firefly luciferase and magnetically sorted 
them into CD62L+ and CD62L– subsets. We then adoptively trans-
ferred the sorted cells to NSG mice. Longitudinal bioluminescent 
imaging demonstrated that the signal from CD62L– cells could be 
detected until day 2, whereas CD62L+ cells remained detectable 
up to day 10 (P < 0.001, Figure 4, A and B). Next, we compared 
the in vivo therapeutic potential of CD62L+ and CD62L– NKT sub-
sets in a model of CAR-redirected immunotherapy for lymphoma. 
NKTs were transduced with a CD19-specific CAR containing 
4-1BB costimulatory endodomain (CAR.CD19, Supplemental Fig-
ure 3) followed by sorting into CD62L+ and CD62L– subsets. NSG 
mice were i.v. injected with luciferase-transduced CD19+ Daudi 
lymphoma cells and 4 days later were divided into 2 groups to 
receive CD62L+ or CD62L– CAR.CD19 NKTs. Both CD62L+ and 
CD62L– CAR.CD19 NKTs prolonged the survival of treated ani-
mals compared with untreated control (P < 0.001). Importantly, 
tion of CD62L+ NKTs during in vitro expansion is due to their 
preferential survival or proliferation in response to antigenic 
stimulation, we measured their rate of cell death and prolifera-
tion after stimulation of the sorted cells with APCs that had been 
pulsed with αGalCer. On day 3 after stimulation, 31% ± 21% and 
74% ± 7.5% of CD62L+ and CD62L– NKTs underwent apoptosis, 
respectively (Figure 3A). We also observed a much greater rate 
of proliferation in CD62L+ versus CD62L– subsets as measured 
by CFSE dilution on day 6 (Figure 3B). Moreover, the major-
ity of cells that survived and proliferated in the CD62L– group 
expressed CD62L, suggesting that these cells were progenies of 
a small subset of CD62L+ cells in the original CD62L– fraction. 
Consistent with these results, we observed a striking difference 
in the numbers of NKTs generated after a 6-day culture of sort-
ed CD62L+ versus CD62L– NKTs with IL-2 alone or with TCR-
stimulation. Indeed, Figure 3C (top panel) demonstrates that 
CD62L+ cells underwent 2.5- and 8-fold numeric expansion with 
IL-2 alone or with TCR-stimulation, respectively. In contrast, 
CD62L– NKTs failed to expand in either condition. Although the 
degree of NKT proliferation in response to antigenic stimulation 
varied from donor to donor, the CD62L– subset contributed little 
or nothing to NKT expansion in all 5 tested donors (Figure 3C, 
Figure 2. CD62L+ and CD62L– NKTs have comparable 
cytotoxicity, but CD62L+ subset is the main source of 
cytokines. (A) Luciferase-transduced CD1d+ DAOY cells 
were pulsed with PBS (control) or αGalCer overnight fol-
lowed by coculture with CD62L+ or CD62L– magnetically 
sorted NKTs. Cytotoxicity was analyzed after 4 hours by 
measurement of luminescence intensity with a plate 
reader. Left plot is a representative of 3 donors (in 
triplicates) with no difference in cytotoxicity between 
NKT subsets. Shown is mean ± SD, n = 3. Right plot is a 
representative of 3 donors (in triplicates) with a signifi-
cant difference in cytotoxicity between NKT subsets. 
Shown is mean ± SD, n = 3. (B) The concentrations of 
IFN-γ and IL-4 were measured in 24-hour supernatants 
of αGalCer-stimulated CD62L+ or CD62L– NKTs by the 
Luminex assay in 3 independent experiments with 
NKTs from 3 donors. ****P < 0.0001, paired t test.
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While resting NKTs express CD28 (Supplemental Figure 1C), they 
express little or no late costimulatory receptors such as 4-1BB and 
OX40 (Supplemental Figure 4A). However, stimulation of NKTs 
with αGalCer-pulsed autologous peripheral blood mononuclear 
cells (PBMCs) resulted in rapid induction of 4-1BB in all NKTs and 
OX40 in CD4+ NKTs (Supplemental Figure 4A). Because CD62L 
is transiently downregulated within the first 24–48 hours after 
TCR-stimulation (data not shown), we analyzed the kinetics of 
4-1BB and OX40 expression in CD62L+ and CD62L– NKTs that 
only CD62L+ CAR-NKTs induced sustained tumor regression, 
with 7 of 9 treated animals alive, 5 of which were tumor-free, for 
at least 3 months. In contrast, all 10 mice treated with CD62L– 
CAR-NKTs succumbed to tumor progression (P < 0.001, Figure 4, 
C and D). Thus, CD62L+ NKTs have extended in vivo persistence 
and superior therapeutic potential compared with CD62L– NKTs.
Costimulation maintains CD62L+ NKTs and prevents exhaus-
tion. There is growing evidence that costimulation plays a criti-
cal role in the activation, survival, and expansion of NKTs (40). 
Figure 3. CD62L+ NKTs have superior survival and proliferative capacity upon 
secondary stimulation. (A) CFSE-labeled NKTs were magnetically sorted into CD62L+ 
and CD62L– subsets as confirmed by post-sorting FACS (top plot) and stimulated with 
irradiated αGalCer-pulsed APCs. On day 3 after stimulation, staining for annexin V 
and 7-AAD was analyzed in NKTs by FACS after gating on CFSE+ events. Results are 
from a representative of 5 donors tested (middle panel). The corresponding bar graph 
(bottom panel) shows mean ± SD of percent annexin V+ NKTs on day 3 (n = 5). (B) Cell 
proliferation was assessed on day 6 after stimulation as measured by CFSE dilution. 
Results are from a representative of 5 donors tested (top panel) and mean ± SD of 
CFSE MFI for all donors (n = 5, bottom panel). (C) Total cell counts were performed at 
the indicated time intervals after NKT stimulation. Shown is mean ± SD (n = 3) viable 
cells for a representative donor (top panel) or fold change for each of 5 donors tested 
on day 6 after stimulation. **P < 0.01, ***P < 0.001, paired t test.
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Figure 4. CD62L+ NKTs have superior in vivo persistence and antitumor activity. (A) Luciferase-transduced NKTs were sorted into CD62L+ and CD62L– 
subsets and injected to NSG mice. NKT in vivo persistence was monitored with bioluminescence imaging. Data are from 1 of 2 independent experiments, 
5 mice per group. (B) Mean ± SD of bioluminescence photon count on indicated days after injection of CD62L+ or CD62L– NKTs. Data are from the same 
experiment shown in A (P = 0.008, paired t test). (C) Each mouse received i.v. injection of 2 × 105 luciferase-transduced Daudi lymphoma cells (day 0) fol-
lowed by (day 4) i.v. injection of 107 CAR.CD19-transduced NKTs with IL-2 (1,000 U/mouse) or PBS as a control. Tumor growth was monitored using biolumi-
nescent imaging once per week (10 mice per group). (D) Survival probability was analyzed by the Kaplan-Meier method (10 mice per group). The differences 
in survival were then compared using the log-rank test. ***P < 0.001.
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Figure 5. Costimulation maintains CD62L+ NKTs and prevents exhaustion. (A) NKTs were sorted into CD62L+ and CD62L– subsets and stimulated and 
examined for expression of 4-1BB and OX40 by FACS before and 3 days after stimulation with αGalCer. Shown are plots from a representative of 4 donors. 
(B) CD62L+ NKTs were stimulated on plates coated with the indicated agonistic mAbs. Shown is mean ± SD (n = 4) of fold change in absolute NKT number 
on day 7 after stimulation compared with day 0. (C) CD62L+ NKTs were stimulated as in B and analyzed for CD62L expression (black) versus isotype control 
(gray) on day 7. Shown are representative overlay histograms (left panel) and mean ± SD of percent CD62L+ cells, n = 4. (D) CD62L+ NKTs were stimulated as 
in B and analyzed for the expression of PD-1 (black) versus isotype control (gray) on day 12. Shown are representative overlay histograms (left panel) and 
mean ± SD of percent PD-1+ cells. *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA.
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or both. OX40 was not tested in these settings because we could 
not obtain an anti-OX40 mAb with an agonistic activity. First, 
we found that costimulation with either anti-CD28, anti–4-1BB 
mAb, or both increased the number of NKTs generated in culture 
within 7 days compared with stimulation with anti-CD3 alone at 
20 ng/ml (P < 0.001, Figure 5B). In the absence of costimulation, 
increasing the concentration of OKT3 from 20 ng/ml to 1 μg/ml 
did not affect the number of NKTs generated, while costimulation 
was effective in increasing NKT number only when it was com-
bined with the lower concentration of OKT3 (Supplemental Fig-
ure 5). Importantly, on day 7 after stimulation with OKT3 alone 
less than half the NKTs were positive for CD62L. The addition 
of anti-CD28, anti–4-1BB, or anti-CD28 with anti–4-1BB mAbs 
resulted in the retention of CD62L expression on 58% ± 7.1% (P = 
0.026), 73% ± 9.2% (P = 0.0036), and 73% ± 6.1% (P = 0.0002) of 
NKTs, respectively (Figure 5C). Coordinately with the retention 
of CD62L expression, NKTs provided with costimulatory signals 
expressed significantly less PD-1 (P < 0.05, Figure 5D). Therefore, 
engagement of costimulatory receptors during antigenic stimula-
tion supports CD62L expression in proliferating NKTs and pre-
vents their exhaustion.
Generation of HLAnull CD1d-expressing aAPCs with costimula-
tory ligands. We hypothesized that, given the observed protective 
effect of costimulation on TCR-activated NKTs, the optimal com-
bination of costimulatory ligands could enable the generation of 
an effective aAPC for clinical-scale expansion of NKTs with high 
were sorted before stimulation. We found that 71.13% ± 18.66% 
and 51.98% ± 18.83% of CD62L+ and CD62L– NKTs, respectively, 
upregulated OX40 within 72 hours after stimulation (P = 0.0072, 
Figure 5A). Similarly, stimulated CD62L+ NKTs expressed a higher 
level of 4-1BB compared with CD62L– NKTs (P = 0.011, Figure 5A). 
OX40 was preferentially upregulated in the CD4+ subset of either 
CD62L+ or CD62L– NKTs, whereas 4-1BB was upregulated in all 
NKTs (Supplemental Figure 4B).
Next, we asked whether costimulation could counteract 
exhaustion of in vitro expanded NKTs. CD62L+ sorted NKTs 
were stimulated on plates coated with an anti-CD3 agonistic 
mAb, OKT3, alone or in combination with mAbs for CD28, 4-1BB, 
Table 1. Phenotype of aAPC clonesA
Clone name Phenotype
22 CD1d+
A-2-1 CD1d+CD86+
A-6-2 CD1d+CD86+4-1BBL+
B-6-1 CD1d+CD86+OX40L+
B-8-2 CD1d+CD86+4-1BBL+OX40L+
AHLAnull K562 cells were transduced with cDNA of human CD1d alone or 
with the indicated costimulatory ligands followed by single-cell sorting by 
FACS, clonal expansion, and immunophenotyping by flow cytometry.
Figure 6. Generation of functional characterization of costimulatory aAPCs for NKT expansion. (A) CD1d+HLAnull K562 clones were transduced with the 
costimulatory molecules, indicated in Table 1, irradiated, and pulsed with αGalCer to stimulate NKTs. NKTs were counted on day 12 after stimulation. Shown 
is mean ± SD (n = 3) of fold increase in NKT absolute number compared with day 0 for each aAPC clone from a representative of 8 experiments performed 
in triplicates. All groups were compared with the group in which NKTs were stimulated with autologous PBMCs, 1-way ANOVA. (B) After primary expansion 
with αGalCer-pulsed autologous PBMCs, NKTs from 4 donors were restimulated with αGalCer-pulsed B-8-2 clone followed by culture with IL-2. The absolute 
count of NKTs was performed at the indicated time intervals (n = 4). (C) After primary expansion with αGalCer-pulsed autologous PBMCs, NKTs were 
restimulated with autologous PBMCs or with B-8-2. CD62L expression was analyzed by FACS on day 12 using NKTs from 3 donors. P < 0.001, paired t test.
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Functional properties of NKTs expanded with aAPCs. Numer-
ous studies have demonstrated that the therapeutic potential of 
NKTs largely relies on their potent effector functions including 
cytotoxicity and cytokine production (11). To examine the effect 
of aAPCs on the functionality of NKTs, we expanded NKTs using 
PBMCs or B-8-2 and compared resultant NKTs using in vitro 
cytotoxicity and cytokine quantification assays. First, we tested 
direct NKT cytotoxicity against CD1d+ DAOY medulloblastoma 
cells (41). Figure 7A demonstrates that NKTs expanded with 
B-8-2 and PBMCs mediated equally potent cytotoxicity against 
DAOY cells, killing 90% of tumor cells at a 5:1 effector-to-target 
ratio. We then transduced NKTs that were expanded with B-8-2 
or PBMCs with CAR.CD19 (Supplemental Figure 7) and found 
that both CAR-NKT preparations were equally cytotoxic against 
CD19+ Raji lymphoma cells, which were not killed by the paren-
tal NKTs (Figure 7B). Next, we stimulated NKTs with αGalCer 
presented by the corresponding APCs used for their expansion 
and measured production of Th1/Th2 cytokines using a multi-
plex Luminex assay. Figure 7C demonstrates that, compared 
with NKTs expanded and restimulated with PBMCs, those 
expanded and restimulated with B-8-2 produced significantly 
higher amounts of IFN-γ and GM-CSF, equal amounts of IL-4, 
and less IL-10 (P < 0.001). We also performed NKT stimulation 
with an agonistic 6B11 mAb, which binds to the CDR3 region of 
their TCR (42), and found that while IL-10 in PBMC-stimulated 
NKTs was largely derived from the PBMCs, B-8-2–expanded 
NKTs still produced larger amounts of IFN-γ and GM-CSF than 
those expanded with PBMCs (data not shown). Therefore, B-8-2– 
therapeutic potential. To test this hypothesis, we rendered K562 
cells HLAnull by eliminating the HLA-Cw3 gene (the only HLA 
allele) using an HLA-C–specific zinc finger nuclease (ZFN) fol-
lowed by transduction with CD1d, CD86, 4-1BBL, and OX40L 
cDNA. HLAnullCD1d+ clones expressing 1, 2, or all 3 costimula-
tory ligands were generated after single-cell FACS sorting, pro-
ducing a total of 161 clones (Supplemental Figure 6A, and Meth-
ods section). Because the level of cell surface expression of the 
transduced ligands varied, we first compared the aAPC activity 
of clones within each subgroup. We then compared the best per-
formers from each subgroup to one another (Table 1). Figure 6A 
demonstrates that clone B-8-2 with the phenotype HLAnullCD1dmed 
CD86high4-1BBLmedOX40Lhigh (Supplemental Figure 6B) consis-
tently induced the highest rate of NKT expansion compared with 
other clones (P < 0.001), producing numbers of NKTs similar 
to the numbers produced by autologous PBMCs (P > 0.05, Fig-
ure 6A). Next, we tested whether the B-8-2 clone was capable 
of propagating NKTs to clinically sufficient numbers. Figure 6B 
demonstrates that 1 round of restimulation with B-8-2 produced 
272.32 ± 111–fold expansion of NKTs from 4 donors (range from 
156 to 424) within 3 weeks, similar to the NKT numbers gener-
ated after stimulation with autologous PBMCs (18). However, 
NKTs expanded with B-8-2 contained significantly higher fre-
quencies of CD62L+ cells compared with PBMC-expanded NKTs 
(P = 0.0089, Figure 6C). Therefore, we selected B-8-2, an aAPC 
clone that coexpressed 3 costimulatory ligands and produced the 
highest rate of NKT in vitro expansion with the maximal preser-
vation of CD62L expression.
Figure 7. Functional characterization of NKTs expanded with 
B-8-2. (A) Luciferase-transduced CD1d+ DAOY cells were pulsed 
with αGalCer overnight followed by coculture with NKTs that were 
expanded after restimulation with PBMCs or B-8-2 aAPCs. Cytotox-
icity was calculated after 4 hours by measurement of luminescence 
intensity with a plate reader. Shown is a representative of 3 experi-
ments in triplicates, mean ± SD (n = 3). (B) NKTs were transduced 
with a CD19-specific CAR followed by expansion of transduced (CAR) 
or nontransduced (NT) NKTs with PBMC or B-8-2 restimulation. The 
cytotoxicity against luciferase-transduced Raji cells was analyzed 
as in A. Shown is a representative of 3 experiments in triplicates, 
mean ± SD (n = 3). (C) NKTs were expanded after restimulation with 
PBMCs or B-8-2 and on day 12 were stimulated with the correspond-
ing APCs pulsed with αGalCer. The concentrations of IFN-γ and IL-4 
were measured in 24-hour supernatants by Luminex assay. Shown 
is a representative of 3 experiments in triplicates, mean ± SD (n = 3). 
***P < 0.001, unpaired t test.
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CD19 followed by adoptive transfer to NSG mice that were pre-
implanted with Raji lymphoma cells. Figure 8A demonstrates that 
CAR expression had little effect on NKT persistence, but NKTs 
propagated with B-8-2 persisted significantly longer than those 
propagated with PBMCs regardless of CAR expression (P < 0.001). 
Importantly, B-8-2–expanded CAR.CD19 NKTs significantly pro-
longed animal survival compared with PBMC-expanded CAR.
CD19 NKTs in 2 B cell lymphoma models (P < 0.001, Figure 8B 
and Supplemental Figure 8). To test whether the observed thera-
peutic superiority of NKTs that we had expanded with our engi-
neered aAPCs also applies to their use against other types of 
cancer and target antigens, we used a metastatic model of neuro-
propagated NKTs possess high levels of CD1d-dependent and 
CAR-redirected cytotoxicity and a Th1-biased cytokine profile.
aAPC-expanded NKTs have superior in vivo persistence and ther-
apeutic activity. Accumulating evidence indicates that the clinical 
efficacy of CAR-T cell therapy against B cell malignancies criti-
cally depends on the in vivo persistence of transferred cells (43–
46), which is influenced by the type of costimulation (44, 47) and 
phenotypic composition of CAR-T cells (48). Since we observed 
that the expansion of NKTs with B-8-2 affects their phenotypic 
composition by increasing the content of CD62L+ cells, we com-
pared the in vivo persistence of NKTs expanded with PBMCs and 
B-8-2. NKTs were transduced with luciferase alone or with CAR.
Figure 8. aAPC-expanded NKTs have superior in vivo persistence and antitumor activity. (A) NKTs were transduced with a CD19-specific CAR followed by 
expansion of transduced (CAR) or nontransduced (NT) NKTs with PBMC or B-8-2 restimulation. Four groups of mice then received i.v. injection of 2 × 105 
Raji cells (day 0) followed by (day 3) i.v. injection of the respective NKT preparations (107 cells per mouse) with IL-2 (1,000 U/mouse). NKT persistence was 
monitored by bioluminescent imaging on the indicated days. Bioluminescent images of 7 mice per group are shown from 1 of 2 independent experiments. 
(B) Mice received i.v. injection of 2 × 105 luciferase-transduced Raji cells (day 0) followed by (day 2) i.v. injection of 107 NT or CAR.CD19 NKTs with IL-2  
(1,000 U/mouse). (C) Mice received i.v. injection of 106 luciferase-transduced CHLA-255 cells (day 0) followed by (day 4) i.v. injection of 107 NT or CAR.GD2 
NKTs with IL-2 (1,000 U/mouse). Tumor growth was monitored using bioluminescent imaging once per week. Survival plot from 2 combined experiments 
for the Raji model (15 mice per group) and 1 experiment with the CHLA-255 model (8 mice per group). Data were analyzed by the Kaplan-Meier method. The 
differences in survival were then compared using the log-rank test. ***P < 0.001.
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CD62L may represent a common marker of cells responsible 
for the long-term maintenance of peripheral NKT and T cells. 
Graef et al. demonstrated that CD62L+ central memory T cells pos-
sess stem cell properties; they could propagate themselves while 
giving rise to effector-memory and effector T cells (36). In the most 
recently published study, Sommermeyer et al. demonstrated that 
human CAR.CD19-expressing CD8 or CD4 T cells generated from 
naive and central-memory subsets were more effective against Raji 
lymphoma xenografts compared with those generated from effec-
tor-memory subsets (38). The authors also found that combining 
the most potent CD4+ and CD8+ CAR-expressing subsets produced 
synergistic antitumor activity in vivo. Activation of NKTs has been 
shown to lead to transactivation of NK and CD8 T cells in murine 
models and in human clinical trials (6, 54), so that the combination 
of CAR-NKTs with other defined subsets of CAR-expressing lym-
phocytes may be a useful therapeutic strategy.
LEF1 and IL7RA were among the immune-related genes that 
were most overexpressed in CD62L+ compared with CD62L– NKTs. 
In a recent report, Carr et al. demonstrated a unique function of 
LEF1 in the expansion of murine Vα14-invariant (iNKT) cells dur-
ing stage 2 of their thymic development via direct transcriptional 
activation of CD127 and c-MYC gene expression (39). Consistent 
with our observation of the coordinated expression of LEF1 and 
GATA3 in human NKTs, these investigators also found that LEF1 
upregulates transcription factor GATA3, which is required for IL-4 
production in iNKT2 cells as well as for dual production of IL-4 
and IFN-γ in iNKT1 cells. The latter cells closely resemble human 
peripheral blood NKTs, in which we found that CD62L+ cells pref-
erentially express GATA3 and produce high levels of both cyto-
kines. Taking the Carr et al. study with murine NKTs and our own 
results with human NKTs, we suggest that LEF1 plays a critical role 
at early stages of NKT development and controls their number 
and function. The high level of LEF1 expression in CD62L+ and its 
loss in CD62L– subsets of human NKTs is consistent with a model 
of linear progression from less differentiated CD62L+ NKTs with 
a preserved proliferative potential and Th0-like cytokine profile 
toward terminally differentiated CD62L– NKTs with diminished 
ability to proliferate and produce cytokines.
There is growing evidence that costimulation plays a critical 
role in the development, activation, and functional responses of 
NKTs in murine models (40, 55). However, little is known about 
the expression of costimulatory receptors in human NKTs. In this 
study, we focused on a set of costimulatory receptors that have 
pronounced prosurvival properties in human T cells: CD28, 4-1BB, 
and OX40 (56–58). First, we confirmed that freshly isolated 
human NKTs express CD28 (34) and showed that they coexpress 
CD27, thereby resembling the corresponding stage of memory T 
cell differentiation with preserved functional potential (35). To our 
knowledge, the current study is the first to characterize the base-
line and post-stimulation kinetics of 4-1BB and OX40 in human 
NKTs. We found that both receptors are undetectable in freshly 
isolated NKTs but are induced following TCR-stimulation. Like 
T cells (59), human NKTs preferentially upregulated OX40 in the 
CD4+ subset. The majority of NKTs also upregulated 4-1BB, which 
is preferentially upregulated in the CD8+ subset of T cells (60). 
Importantly, we found that costimulation of individual costimula-
tory receptors could inhibit the loss of CD62L expression and res-
blastoma with a multi-drug-resistant CHLA-255 human neuro-
blastoma cell line (49) and NKTs expressing a GD2-specific CAR. 
Figure 8C demonstrates that CAR.GD2 NKTs that were expanded 
with aAPCs had potent antitumor activity compared with untreat-
ed control (P < 0.001), whereas those expanded with PBMCs 
were ineffective. Therefore, expansion of NKTs using B-8-2 
aAPCs confers a qualitative advantage to NKTs, enabling superior 
in vivo persistence and antitumor activity.
Discussion
A critical gap in knowledge of human NKT biology has slowed 
down the development of effective NKT-based cancer immuno-
therapy. We found that NKT numeric ex vivo expansion and sub-
sequent in vivo persistence — essential requirements for effective 
NKT-based cell and gene therapy applications — depend on the 
CD62L+ subset of peripheral blood NKTs. Only CD62L+ NKTs 
survive and proliferate in response to repeated TCR-stimulation, 
while CD62L– cells undergo early exhaustion and cell death. 
Although continuous stimulation of NKTs is associated with the 
loss of CD62L expression, activation of costimulatory receptors 
during TCR-stimulation can counteract this process. Specifically, 
we experimentally determined a unique combination of CD86, 
4-1BBL, and OX40L molecules and the levels of their coexpres-
sion on the surface of an aAPC that enables highly efficient clin-
ical-scale NKT expansion with maximal preservation of CD62L 
expression. CAR-NKTs generated using the aAPCs developed in 
the course of this study demonstrated extended in vivo persis-
tence and superior therapeutic activity against in vivo models of 
lymphoma and neuroblastoma.
We show that the CD62L+ subset is responsible for the numeric 
expansion of NKTs upon antigenic stimulation ex vivo. The fol-
lowing findings support the above conclusion: (a) the fraction of 
CD62L+ cells is dramatically increased after primary NKT stimu-
lation; (b) the majority of sorted CD62L– cells undergo apoptosis, 
whereas sorted CD62L+ cells proliferate in response to identical 
stimulation; and (c) CD62L– NKTs exhibit signs of terminal differ-
entiation (CD161 and CD56 expression) in freshly isolated PBMCs 
and rapidly acquire an exhaustion phenotype upon in vitro stimu-
lation as evidenced by marked upregulation of PD-1 and TIM-3 
expression and diminished ability to produce cytokines. When sim-
ilar characteristics are observed in T cell therapeutic products, they 
are associated with a subsequent lack of persistence or of objective 
responses after adoptive transfer to cancer patients (50, 51).
We observed that proliferating NKTs eventually downregu-
late CD62L expression and acquire an exhaustion phenotype dur-
ing in vitro culture. This observation likely reflects the ontogeny 
of human peripheral NKTs, as the frequency of CD62L+ NKTs is 
lower in adult peripheral blood compared with cord blood (33, 52). 
In 1 report, cord blood NKTs were found not to express CD62 (31). 
The reason for the discrepancy between that report and others 
and with our own results is not clear and is likely to be technical. 
Constantinides et al. identified a very rare naive-like population of 
CD1d-restricted T cells with a high level of CD62L in peripheral 
blood (53). However, these cells do not express the invariant Vα24 
chain and have a lower level of PLZF expression compared with 
the classical NKTs. Both CD62L+ and CD62– NKTs in this study 
expressed equally high levels of PLZF.
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could be maximized. Further enhancement of CAR-NKT per-
sistence and antitumor efficacy could be achieved by providing 
optimal costimulatory signals within CAR constructs such as 
CD28 or 4-1BB costimulatory endodomains that are critically 
important for the clinical efficacy of CAR.CD19 T cells (19, 20). 
The optimal costimulatory CAR design for NKTs is yet to be 
found. It will be interesting to determine the role of the CD62L+ 
subset in CAR-mediated NKT proliferation and persistence. Ulti-
mately, the development of an effective NKT-based CAR-redi-
rected cancer immunotherapy will likely require the coordinated 
use of costimulation provided by aAPCs during ex vivo expan-
sion and CAR after adoptive transfer to patients.
Methods
Cell lines and culture conditions. The parental K562 cells were provided 
by C. June (University of Pennsylvania, Philadelphia, PA). Daudi, Raji, 
DAOY, and 293T cells were purchased from American Type Culture Col-
lection (ATCC). The CHLA-255 cell line was previously described (49). 
K562, Daudi, Raji, and CHLA-255 cells were cultured in RPMI, whereas 
DAOY and 293T cells were maintained in Iscove’s Modified Dulbecco’s 
Medium (IMDM; Invitrogen). Both types of medium were supplemented 
with 10% FBS (HyClone), 2 mM GlutaMAX-1 (Gibco-BRL).
NKT isolation, transduction, expansion, and sorting. To analyze the 
cord blood NKTs we used discarded cord blood units obtained from 
the MD Anderson Cancer Center Cord Blood Bank according to the 
protocols approved by the IRBs at MD Anderson Cancer Center and 
Baylor College of Medicine (BCM). PBMCs of healthy donors (at least 
18 years old) were isolated by gradient centrifugation from buffy coats 
purchased from Gulf Coast Regional Blood Center. NKTs were puri-
fied by anti-iNKT microbeads (Miltenyi Biotec). The negative PBMC 
fraction was irradiated (40 Gy) and aliquoted. NKTs were stimulated 
with an aliquot of autologous PBMCs pulsed with 100 ng/ml αGalCer 
(Kyowa Hakko Kirin). Recombinant IL-2 (200 U/ml; National Can-
cer Institute Frederick) was added every other day in complete RPMI 
(HyClone RPMI 1640, 10% heat-inactivated FBS, and 2 mM Gluta-
MAX). NKTs were expanded for 10 days and then restimulated with 
autologous PBMCs (irradiated with 40 Gy) or aAPCs (irradiated with 
100 Gy) when indicated. On day 3 after restimulation, 24-well, non–
tissue culture plates were coated with retronectin (Takara Bio) and, 
after washing, inoculated with 1 ml of retroviral supernatant contain-
ing CAR.CD19 and spun for 60 minutes at 4,600 g. The viral superna-
tant was then removed, and stimulated NKTs were added to the wells 
in complete media and 200 U/ml recombinant human IL-2. Cells were 
removed from the plate after 48 hours, washed, resuspended at the 
concentration 106 cells/ml in complete RPMI with 200 U/ml IL-2, and 
plated for continued expansion. NKT number was determined by try-
pan blue (Life Technologies) counting. When indicated, NKTs or CAR-
NKTs were labeled with CD62L-PE mAb (GREG-56; BD Biosciences) 
and anti-PE microbeads (Miltenyi) followed by magnetic sorting into 
CD62L+ and CD62L– subsets according to the manufacturer’s instruc-
tions. The phenotype of the sorted cells was determined by FACS.
Retroviral constructs and retrovirus production. CAR.CD19 and CAR.
GD2 constructs were made as previously described (18, 73) and con-
tained a single-chain variable fragment from the CD19-specific antibody 
FMC-63 or the GD2-specific antibody 14G2a connected via a short spac-
er derived from the IgG1 hinge region to the transmembrane domain 
derived from CD8α, followed by signaling endodomain sequences of 
cue NKTs from exhaustion. We also observed an additive effect 
on the maintenance of CD62L+ NKTs when CD28 and 4-1BB were 
simultaneously activated.
Several types of aAPCs have been developed from the K562 
cell line for clinical-scale numeric expansion of T and NK cells 
for adoptive immunotherapy applications (61–63). In the design 
of K562-based aAPCs for NKTs, we sought to selectively acti-
vate and expand NKTs while avoiding competition with T and 
NK cells. K562 cells express only 1 HLA allele, HLA-Cw3, which 
is known to activate NK cells (64). Hence, the deletion of the 
HLA-Cw3 gene and transgenic expression of CD1d in HLAnull 
K562 cells enabled antigen presentation to NKTs without activa-
tion of NK or conventional T cells. Importantly, the B-8-2 clone 
we experimentally selected with the optimal combination of 
costimulatory ligands (and their expression levels) demonstrat-
ed aAPC qualities for NKTs that exceeded those of the autolo-
gous PBMCs. We did, however, observe a differential effect 
on NKT expansion between plate-bound agonistic mAbs and 
the corresponding ligands for costimulatory receptors. While 
costimulation with 1 or 2 mAbs for CD28 or 4-1BB enhanced the 
rate of NKT expansion with retention of CD62L, expression of 
ligands for 3 receptors (CD28, 4-1BB, and OX40) on K562 cells 
was needed to achieve such an effect. This could be explained 
by higher affinity of mAbs to the receptors compared with the 
natural ligands or expression of inhibitory molecules on K562 
cells that counteract NKT activation.
B-8-2–expanded NKTs and CAR-NKTs had superior in vivo 
persistence, one of the critical requirements for the efficacy of 
adoptive cancer immunotherapy. Indeed, we found that B-8-2–
expanded NKTs expressing anti-CD19 and anti-GD2 CARs had 
superior therapeutic activity in B cell lymphoma and neuroblas-
toma models, respectively. In this study, we do not compare NKTs 
or CAR-NKTs with T or CAR-T cells because the xenogenic model 
in NSG mice does not allow such a comparison. It is well docu-
mented that adoptive transfer of human T or CAR-T cells to NSG 
mice leads to the development of xeno-graft-versus-host disease 
(GvHD) (18, 65, 66). The latter report revealed that unless deplet-
ed from CD45RA+ naive cells before ex vivo expansion, human 
T cells with or without anti-CD19 CAR cause severe xenogeneic 
GvHD in addition to antileukemia activity. In contrast, the persis-
tence of human NKTs or CAR-NKTs in mice is not supported by 
the artifact of xenoreactivity to murine tissues (18).
Despite recent successes in the immunotherapy of B cell 
leukemias and lymphomas with CAR-T cells, about half of lym-
phoma patients do not achieve complete responses, and the 
duration of the responses is not yet well established (67, 68). 
NKTs could have a particular advantage as CAR carriers for the 
immunotherapy of B cell malignancies, including lymphomas 
in the settings of allogeneic hematopoietic stem cell transplant 
(HSCT), because NKTs do not induce and even suppress GvHD 
while maintaining graft-versus-leukemia activity (69, 70). More-
over, a recent report demonstrated that reconstitution of NKTs 
in peripheral blood is associated with long-term remission in 
pediatric leukemia patients receiving haploidentical stem cell 
transplantation (71, 72). Hence, unlike donor-derived CAR-T 
cells, CAR-NKTs can be given early after HSCT when the disease 
burden is minimal and the curative potential of immunotherapy 
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
2 3 5 3jci.org   Volume 126   Number 6   June 2016
system as previously described (76). A clone with an intermediate level 
of CD1d expression induced the highest rate of NKT proliferation and 
was further modified with lentiviral vectors encoding CD86, 4-1BBL, 
or OX40L followed by single cell sorting and clonal expansion. The 
generated library of clones was divided into groups based on expres-
sion of 1, 2, or 3 costimulatory molecules.
Gene expression analysis. Total RNA was collected using TRIzol 
reagent (Qiagen). Gene expression analysis was performed using 
Immunology Panel version 2 (NanoString) at BCM Genomic and RNA 
Profiling Core using nCounter Analysis System. Data were analyzed 
using nSolver 2.0 software (NanoString).
In vivo experiments. The colony of NSG mice was originally 
obtained from The Jackson Laboratory and maintained at BCM Ani-
mal Care facility. Tumor growth was initiated by i.v. injection of 2 × 
105 luciferase-transduced Raji lymphoma cells. On day 3, mice were 
treated with 4 × 106 to 8 × 106 CAR-NKTs followed by i.p. injection of 
IL-2 (1,000 U/mouse) every 3 days. Tumor growth was assessed twice 
per week by bioluminescent imaging (Small Animal Imaging core 
facility, Texas Children’s Hospital). For the in vivo persistence experi-
ments, NKTs were cotransduced with CAR.CD19 and luciferase using 
retroviral constructs, i.v. injected to tumor-free or tumor-bearing mice, 
and monitored using bioluminescent imaging twice per week. Animal 
experiments were performed according to IACUC-approved protocols.
Statistics. For in vitro and in vivo experiments, we used 2-sided, 
paired Student’s t test to evaluate continuous variable of 2 groups, 
and 1-way ANOVA with post-test Bonferroni to evaluate continuous 
variables of more than 2 groups. Survival was analyzed by the Kaplan-
Meier method and the log-rank (Mantel-Cox) test to compare pairs of 
groups. Statistics were computed using GraphPad Prism 5.0 (Graph-
Pad Software). Differences were considered significant when the P 
value was less than 0.05.
Study approval. The cord blood units were obtained from MD 
Anderson Cancer Center Cord Blood Bank according to the protocols 
approved by the IRBs at MD Anderson Cancer Center (H-16320) and 
Baylor College of Medicine (H-20911). Written informed consent was 
received from all participating women prior to inclusion in the study 
under the protocol H-16320. Cord blood units not suitable for clinical 
use (usually because of low cell counts) were either discarded or used 
for research purposes under the protocol H-20911 at BCM.
Animal experiments were performed according to the protocol 
AN-5194 approved by the IACUCs of BCM.
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of prevalidated 2-finger and 1-finger modules (Sangamo BioScience). 
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2 such ZFNs (designated as ZFN-L and ZFN-R) could be targeted to 
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assay (76). A clone of HLAnull K562 cells was then electroporated with 
human CD1d cDNA using Sleeping Beauty transposon/transposase 
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